Navigation Links
Study shows AIDS drugs cost-effective, care underfunded

the board: the inadequacy of reimbursement to the treating physicians and clinics.

In the study, medications were the single costliest component, comprising $71 to $84 of every $100 spent, regardless of stage of disease. In sharp contrast, expenditures for physicians' services and clinic fees accounted for less than $2 of every $100, or on average, $360 per patient per year. This is far less than the providers' actual costs, which average approximately $1,500 to 2,000 per patient per year. The study assumed all patients had Medicare health insurance and the clinics were reimbursed 100 percent. "However, the majority of people who are infected with HIV are either uninsured or underinsured" and unable to pay for their care, said Dr. Saag. "So in reality, the actual reimbursement to clinics is markedly less than $360 per patient per year, making the situation even more dire," he added.

As a consequence, said Dr. Saag, "We are approaching a potential crisis in the availability of physicians to provide care for patients? Many private-practice HIV clinics are closing. Most academic institutions within the United States, including ours, are absorbing the cost of care for HIV patients" ?a burden that can range into the millions of dollars, he said. These treatment providers' necessary reliance on federal assistance "underscores the tremendous need for reauthorization of the Ryan White CARE Act with increased resources allocated for reimbursement of medical care, which is now under discussion in Congress," Dr. Saag said.

Although institutions are developing ways to bring down HIV treatment costs, they won't be able to cover those costs themselves indefinitely, Dr. Saag warned. Notwithstanding the promising findings on HAART's cost-effectiveness, "Providing drugs alone is not enough," he said. "We must focus now on creating appropriate incentives for providers to care for HIV patients. The current pool of providers is struggling to make ends meet.
'"/>

Source:Infectious Diseases Society of America


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study shows AIDS drugs cost effective care underfunded

(Date:7/30/2014)... The Governing Board of the Entomological Society of America ... for 2014. The election as a Fellow acknowledges outstanding ... following: research, teaching, extension, or administration. The following Fellows ... Annual Meeting -- which will be held November 16-19, ... BOSQUE-PREZ is a professor with the Department of ...
(Date:7/30/2014)... Press (OUP) is pleased to announce its new relationship ... 2015, OUP and CINP will partner to publish ... a fully open-access journal. , Alan Frazer, Editor-in-Chief of ... size and expertise of OUP will further facilitate the ... of the very leading journals within neuropsychopharmacology. The conversion ...
(Date:7/30/2014)... of biologists, led by Clemson University associate professor Andrew ... that will pave the way for novel anti-fouling paint ... medical and industrial applications. , The team,s findings, published ... last larval stage of barnacles that attaches to a ... polymeric material that acts as an underwater heavy-duty adhesive. ...
Breaking Biology News(10 mins):Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17OUP to partner with the International College of Neuropsychopharmacology 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... battle against insect pests, new research indicates that it ... A group of Rockefeller University scientists who had previously ... smell in fruit flies now shows that this gene's ... insect species. , Research by Leslie Vosshall's laboratory had ...
... Researchers at the University of Bath have won a £261,000 ... of a designer drug that could stop influenza and some ... the grant comes at a time when fears are rising ... thousands of people. , Professor Ian Williams, of the Department ...
... researchers present a “cautionary tale?about what may go wrong when ... test for cancer. , In the February 16 issue of ... University of Texas M. D. Anderson Cancer Center detail why ... a small sample of blood is unlikely to lead to ...
Cached Biology News:Ancient olfaction protein is shared by many bugs, offering new pest control target 2Computers to be used to find blueprint for new influenza drug 2New species from old data 2New species from old data 3
(Date:7/30/2014)... BROOK, NY (PRWEB) July 30, 2014 ... APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based ... Michael E. Hogan, Ph.D. Vice President of Life Sciences, ... mid-September. , Dr. Hogan will lead APDN’s ... form business relationships with biotech and healthcare customers, provide ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... , EMERYVILLE, Calif. , June 1 Onyx Pharmaceuticals, ... 1 study of ONX 0912, an oral proteasome inhibitor, in patients with ... , , ... program and ONX 0912,s favorable preclinical profile – anti-tumor activity, safety and ...
... ... Consortium Using Systems Biology to Study Infectious Diseases , ... (PRWEB) June 1, 2010 -- Genedata, a leading ... it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is ...
... ... incorporating BioSoteria’s eLadder® Safety course series into its curriculum. The online drug safety ... pharmacovigilance, accessible to enrolled PharmD and PhD students, postdoctoral fellows, and residents via the ... ...
Cached Biology Technology:Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 2Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 3Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors 4Genedata Phylosopher Selected for ERA-NET sncRNA Project 2Genedata Phylosopher Selected for ERA-NET sncRNA Project 3Genedata Phylosopher Selected for ERA-NET sncRNA Project 4University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Biology Products: